Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc.

Shares in biopharmaceutical company Arcus Biosciences ($RCUS) collapsed 17% in pre-market trading after it said it was stopping a late-stage study ...

Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences, with a price target of $150.00. Bansal co...

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

In a report released yesterday, Carter Gould from Cantor Fitzgerald maintained a Buy rating on Gilead Sciences, with a price target of $135.00. Gou...

Cantor Fitzgerald Remains a Buy on Gilead Sciences (GILD)

In a report released on November 26, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences, with a price target of $135.00. The ...

Gilead Sciences (GILD) Gets a Buy from Bernstein

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Gilead Sciences ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gilead Sciences ( ($GILD) ) has provided an update. On November 19, 2025, Gilead Sciences announced that Deborah H. Telman will step down from her ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GILD	$120.40	-2.28%	6.77M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GILD	$120.40	-2.3%	6.77M
3
4
5
6

GILD

GILD

Get Gilead Sciences Inc. Data in Excel

Get Gilead Sciences Inc. Data in Excel